- $683.91m
- $621.11m
- $837.60m
- 63
- 67
- 19
- 48
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 52.87 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.98 | ||
| Price to Tang. Book | 4.49 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.82 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -14.05% | ||
| Return on Equity | -17.15% | ||
| Operating Margin | -14.48% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 638.6 | 690.6 | 678.4 | 753.2 | 837.6 | 844.87 | 915.55 | -0.32% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +244.3 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Directors
- S. Louise Phanstiel CHM (62)
- Paul Diaz PRE (59)
- R. Bryan Riggsbee CFO (49)
- Melissa Gonzales CEX
- Mark Verratti CEX (52)
- Faith Zaslavsky CEX
- Nicole Lambert COO (47)
- Benjamin Jackson EVP (41)
- Jayne Hart EVP (60)
- Paul Parkinson EVP (54)
- Jeff Borcherding SVP
- Maggie Ancona SVP
- Edward Gala SVP
- David Hammer SVP
- Chris Williamson SVP
- Kevin Haas CTO
- Justin Hunter VPR
- Karen Renner VPR
- Jackie Zou VBD
- Eric Santa OTH
- Thomas Slavin OTH
- Gwendolyn Turner OTH
- Pamela Wong OTH
- Heiner Dreismann IND (68)
- Rashmi Kumar IND (51)
- Dennis Langer IND (69)
- Lee Newcomer IND (69)
- Colleen Reitan IND (61)
- Daniel Skovronsky IND (47)
- Daniel Spiegelman IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 6th, 1992
- Public Since
- October 6th, 1995
- No. of Shareholders
- 88
- No. of Employees
- 2,700
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 92,171,423
- Address
- 322 North 2200 West, SALT LAKE CITY, 84116
- Web
- https://myriad.com/
- Phone
- +1 8015843600
- Contact
- Matt Scalo
- Auditors
- Ernst & Young LLP
Upcoming Events for MYGN
Myriad Genetics Inc Annual Shareholders Meeting
Myriad Genetics Inc Annual Shareholders Meeting
Q2 2025 Myriad Genetics Inc Earnings Release
Similar to MYGN
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Myriad Genetics share price?
As of Today at 22:10 UTC, shares in Myriad Genetics are trading at $7.42. This share price information is delayed by 15 minutes.
How has the Myriad Genetics share price performed this year?
Shares in Myriad Genetics last closed at $7.42 and the price had moved by -58.73% over the past 365 days. In terms of relative price strength the Myriad Genetics share price has underperformed the S&P500 Index by -61.91% over the past year.
What are the analyst and broker recommendations for Myriad Genetics?
The overall consensus recommendation for Myriad Genetics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Myriad Genetics dividend yield?
Myriad Genetics does not currently pay a dividend.
Does Myriad Genetics pay a dividend?
Myriad Genetics does not currently pay a dividend.
When does Myriad Genetics next pay dividends?
Myriad Genetics does not currently pay a dividend.
How do I buy Myriad Genetics shares?
To buy shares in Myriad Genetics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Myriad Genetics?
As of the previous close price of $7.42, shares in Myriad Genetics had a market capitalisation of $683.91m.
Where are Myriad Genetics shares listed?
Here are the trading details for Myriad Genetics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: MYGN
What kind of share is Myriad Genetics?
Based on an overall assessment of its quality, value and momentum Myriad Genetics is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Myriad Genetics share price forecast for 2025?
The analyst consensus target price for shares in Myriad Genetics is $15.03. That is 102.56% above the last closing price of $7.42.
Analysts covering Myriad Genetics currently have a consensus Earnings Per Share (EPS) forecast of $0.08 for the next financial year.
Find out moreWhat is the trend in the Myriad Genetics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Myriad Genetics. Over the past six months, its share price has underperformed the S&P500 Index by -63.73%.
As of the last closing price of $7.42, shares in Myriad Genetics were trading -59.09% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Myriad Genetics PE Ratio?
The Myriad Genetics PE ratio based on its reported earnings over the past 12 months is 52.87. The shares last closed at $7.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Myriad Genetics?
Myriad Genetics' management team is headed by:
- S. Louise Phanstiel - CHM
- Paul Diaz - PRE
- R. Bryan Riggsbee - CFO
- Melissa Gonzales - CEX
- Mark Verratti - CEX
- Faith Zaslavsky - CEX
- Nicole Lambert - COO
- Benjamin Jackson - EVP
- Jayne Hart - EVP
- Paul Parkinson - EVP
- Jeff Borcherding - SVP
- Maggie Ancona - SVP
- Edward Gala - SVP
- David Hammer - SVP
- Chris Williamson - SVP
- Kevin Haas - CTO
- Justin Hunter - VPR
- Karen Renner - VPR
- Jackie Zou - VBD
- Eric Santa - OTH
- Thomas Slavin - OTH
- Gwendolyn Turner - OTH
- Pamela Wong - OTH
- Heiner Dreismann - IND
- Rashmi Kumar - IND
- Dennis Langer - IND
- Lee Newcomer - IND
- Colleen Reitan - IND
- Daniel Skovronsky - IND
- Daniel Spiegelman - IND